Search

H Lundbeck A-S

Open

46.14 0.17

Overview

Share price change

24h

Current

Min

45.44

Max

46.44

Key metrics

By Trading Economics

Income

-186M

966M

Sales

-212M

6B

P/E

Sector Avg

12.977

37.461

EPS

1.35

Dividend yield

2.09

Profit margin

16.039

Employees

5,700

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.09%

2.33%

Market Stats

By TradingEconomics

Market Cap

9.7B

43B

Previous open

45.97

Previous close

46.14

H Lundbeck A-S Chart

Past performance is not a reliable indicator of future results.

Related News

26 Oct 2025, 23:52 UTC

Market Talk

Global Equities Roundup: Market Talk

26 Oct 2025, 23:52 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

26 Oct 2025, 23:46 UTC

Market Talk

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 Oct 2025, 23:41 UTC

Market Talk

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 Oct 2025, 23:34 UTC

Earnings

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 Oct 2025, 23:32 UTC

Earnings

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 Oct 2025, 23:30 UTC

Earnings

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 Oct 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 Oct 2025, 22:29 UTC

Earnings

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 Oct 2025, 22:29 UTC

Earnings

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 Oct 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 Oct 2025, 22:16 UTC

Earnings

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 Oct 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 Oct 2025, 19:29 UTC

Acquisitions, Mergers, Takeovers

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 Oct 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 Oct 2025, 06:39 UTC

Earnings

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 Oct 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 Oct 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Oct 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 Oct 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 Oct 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 Oct 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 Oct 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 Oct 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 Oct 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat